Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2024 (2024-12-31): -509.99%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-178.37%
RETURN ON EQUITY (ROE) AVG 3Y
-80.33%
RETURN ON EQUITY (ROE) AVG 5Y
-54.69%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Sutro Biopharma, Inc.
Market Cap
$141.00M
Return on Equity (ROE)
N/A
TTM Avg
-178.37%
3Y Avg
-80.33%
5Y Avg
-54.69%
Market Cap
$143.10M
Return on Equity (ROE)
-43.40%
TTM Avg
-27.96%
3Y Avg
-44.92%
5Y Avg
-37.65%
Market Cap
$140.49M
Return on Equity (ROE)
-30.03%
TTM Avg
-86.56%
3Y Avg
-69.53%
5Y Avg
-37.30%
Market Cap
$143.10M
Return on Equity (ROE)
-120.33%
TTM Avg
-117.87%
3Y Avg
-76.44%
5Y Avg
-55.77%
Market Cap
$143.67M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$149.01M
Return on Equity (ROE)
-131.85%
TTM Avg
-36.69%
3Y Avg
-135.43%
5Y Avg
-129.92%
Market Cap
$138.23M
Return on Equity (ROE)
-44.26%
TTM Avg
-34.18%
3Y Avg
285.39%
5Y Avg
-5868.11%
Market Cap
$145.54M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$136.88M
Return on Equity (ROE)
-10.08%
TTM Avg
-25.77%
3Y Avg
-36.68%
5Y Avg
-27.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | $141.00M | N/A | -178.37% | -80.33% | -54.69% |
| Protara Therapeutics, Inc. (TARA)vs › | $143.10M | -43.40% | -27.96% | -44.92% | -37.65% |
| Immuneering Corporation (IMRX)vs › | $140.49M | -30.03% | -86.56% | -69.53% | -37.30% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -120.33% | -117.87% | -76.44% | -55.77% |
| Fortress Biotech, Inc. (FBIOP)vs › | $143.67M | 68.12% | -94.32% | -166.28% | -128.51% |
| Korsana Biosciences, Inc. (KRSA)vs › | $149.01M | -131.85% | -36.69% | -135.43% | -129.92% |
| Alpha Cognition Inc (ACOG)vs › | $138.23M | -44.26% | -34.18% | 285.39% | -5868.11% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $145.54M | -183.44% | -114.28% | -67.72% | -46.03% |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.88M | -10.08% | -25.77% | -36.68% | -27.09% |
| Atrium Therapeutics, Inc. (RNA)vs › | $136.41M | -43.42% | -36.99% | -36.99% | -36.99% |
ROE
N/A
ROA
-92.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-12-31 | -509.99% |
| 2024-09-30 | -111.45% |
| 2024-06-30 | -81.78% |
| 2024-03-31 | -117.27% |
| 2023-12-31 | -71.36% |
| 2023-09-30 | -153.50% |
| 2023-06-30 | -92.21% |
| 2023-03-31 | -70.19% |
| 2022-12-31 | -54.92% |
| 2022-09-30 | -53.43% |
| 2022-06-30 | -64.17% |
| 2022-03-31 | -51.86% |
| 2021-12-31 | -41.79% |
| 2021-09-30 | -44.77% |
| 2021-06-30 | -25.66% |
| 2021-03-31 | -13.96% |
| 2020-12-31 | -9.68% |
| 2020-09-30 | 5.17% |
| 2020-06-30 | -8.43% |
| 2020-03-31 | -74.42% |
| 2019-12-31 | -57.00% |
| 2019-09-30 | -38.62% |
| 2019-06-30 | -33.27% |
| 2019-03-31 | -28.70% |
| 2018-12-31 | -26.85% |
